OPT
Opthea Limited - ADR

245
Loading...
Loading...
News
all
press releases
Opthea raises solvency concerns after phase 3 trial fails
Investing.com--U.S. and Australia-listed biopharmaceutical firm Opthea Ltd (NASDAQ:OPT) on Monday raised concerns over its ability to continue operations after a major phase 3 trial did not meet its primary endpoint.
investing.com·6mo ago
News Placeholder
More News
News Placeholder
Opthea Limited Eyes Breakthrough in Vision Treatment
Opthea Limited (AU:OPT) has released an update. Opthea Limited, a company focused on eye-related medical treatments, is making strides in improving...
TipRanks Financial Blog·1y ago
News Placeholder
Opthea Concludes Major Capital Raising Effort
Opthea Limited (AU:OPT) has released an update. Opthea Limited has successfully completed a significant capital raise of approximately A$227.3 mill...
TipRanks Financial Blog·1y ago
News Placeholder
Opthea to Participate in the 23 Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT Opthea , the Company ), a clinical-stage biopharmaceutical company developing novel...
Globe Newswire·1y ago
News Placeholder
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee ChairMELBOURNE, Australia and PRINCETON, N.J., April 03...
Globe Newswire·1y ago
News Placeholder
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to...
Globe Newswire·1y ago
News Placeholder
Short Interest in Opthea Limited (NASDAQ:OPT) Decreases By 21.1%
Opthea Limited (NASDAQ:OPT Get Free Report) was the target of a large drop in short interest in the month of February. As of February 29th, there was short interest totalling 124,100 shares...
Ticker Report·1y ago
News Placeholder
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; Opthea ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Globe Newswire·2y ago
News Placeholder
Financial Review: Opthea (NASDAQ:OPT) vs. Amgen (NASDAQ:AMGN)
Opthea (NASDAQ:OPT Get Free Report) and Amgen (NASDAQ:AMGN Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on...
Zolmax·2y ago

Latest OPT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.